January 7, 2025
Alliance Healthcare UK appoints sales director
Alliance Healthcare UK has appointed Paula Sutherland to the position of Sales Director where she will lead sales teams in…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
January 6, 2025
Clinigen partners with Santhera Pharmaceuticals to expand access to treatment for Duchenne Muscular Dystrophy (DMD) patients
Clinigen, the global pharmaceutical services company, today announces it has signed an exclusive supply and distribution agreement with Santhera Pharmaceuticals (SIX:…
December 16, 2024
ENEA-Tech Biomedical Foundation Invests €6m in BetaGlue Therapeutics
Italian clinical-stage oncology company BetaGlue Therapeutics, developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumours, called YntraDose, announced Monday that the ENEA-Tech and Biomedical Foundation (“ENEA-Tech”) has invested €6m bringing the total raised in the current funding round to €24m.
December 16, 2024
Novo Nordisk to invest 8.5 billion Danish kroner (€1.14B) in new production facility in Denmark.
Novo Nordisk announced Monday it plans to invest 8.5 billion Danish kroner (€1.14B) to establish a completely new production facility in Odense, Denmark.
December 16, 2024
Swiss Basilea partners up with Innoviva to sell anti MRSA antibiotic Zevtera in the US
Basilea Pharmaceutica, a Swiss bacterial and fungal infections biopharmaceutical specialist, has entered into an exclusive distribution and license agreement with…
December 13, 2024
Newron partners up with Japanese EA Pharma
Italian Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, and Japanese EA Pharma, a subsidiary of Eisai Co., Ltd., have entered into a license agreement to develop, manufacture and commercialize Newron’s innovative modulator of the excessive release of glutamate, evenamide, in Japan and other designated Asian territories.
December 13, 2024
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules
Each unit is being sold at an effective offering price of $5.85 per unit, priced at-the-market under Nasdaq rules.
December 13, 2024
HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)
US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe — — Follows June 2024 European approval of FRUZAQLA® (fruquintinib), the first novel oral targeted therapy in the EU for metastatic colorectal cancer regardless of biomarker status in over a decade
December 12, 2024
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
NAARDEN, the Netherlands and MIAMI, Dec. 11, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the…
December 11, 2024
Women urged to put breast density knowledge at the top of their Christmas list
Micrima, a Bristol-based health tech company, is urging women to give themselves the gift of prioritising knowledge of their breast…